直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

“Technical Invention” Exclusion Tempers Broad “Financial Service” Interpretation in CBM Institution Decision

June 19, 2014

Authored and Edited by Justin N Mullen; Jeffrey C. Totten

When is a patent directed at financial services not a “covered business method” under Section 18(d) of the AIA? When it claims a “technological invention.” Experian Mktg. Solutions, Inc. v. RPost Commc’ns Ltd., CBM 2014-0010 (Paper No. 20) (Apr. 22, 2014), the first PTAB decision denying institution of Covered Business Method (CBM) Patent Review, illustrates how the “technological invention” exception limits the scope of CBM review.

Experian involved U.S. Patent Number 8,224,913 (the ‘913 patent), directed to “a method of transmitting a message from a sender to a recipient through a server.” The exemplary claim involves method of authenticating e-mail messages using digital signatures.

In deciding whether to institute CBM review, the Board first considered whether the claims were related to a “financial product or service.” Consistent with earlier institution decisions, the Board construed “financial product or service” broadly, concluding that the claimed messaging system was financially related because it could facilitate “orders” and “offers to purchase.”

Next, the Board considered whether the patent was exempt from CBM review as a “technological invention.” Citing its trial practice guide, the Board first set forth examples of what does not constitute a “technological invention”— “mere recitation of known technologies,” “use of known prior art to accomplish a process,” and “combining prior art structures to achieve the normal, expected or predictable result.”

Turning to the claim at issue, the Board criticized the Petitioner for “analyzing the method steps separately, instead of examining each claim as a whole ...” The fact that aspects of the claim, such as e-mail systems, were well-known before filing of the challenged patent did not lessen the Petitioner’s burden to show the entire claimed method was not a technological invention. According to the Board, the Petitioner failed to demonstrate that the claimed method—including an intermediary recording step that eliminated the need for specialized e-mail systems—was not a technological invention.

As this first denial of a CBM petition illustrates, the “technological invention” exemption tempers the broad definition of “financial product or service” in determining whether to institute CBM review. Petitioners should fully explain why no technical problem is being addressed by the claims, including evidence that the technical features were known at the time of invention.  Further, in addressing this issue, piecemeal analysis will not do; the claims should be analyzed as a whole.

Tags

Section 18(d)(1)

Contacts

Jeffrey C. Totten
Partner
Washington, DC
+1 202 408 4232
Email

Copyright © 2014 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Articles

Article_D.-Mass-Patent-Litigation-Update-October-2024

D. Mass. Patent Litigation Update: April 2026

June 1, 2026

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP